Akari Therapeutics Plc (AKTX) Return on Assets ROA from the first quarter of 2026 to first quarter of 2025 and for the year 2026, Average High and Low, Fundamental Ratios from Mar 31 2026 to Mar 31 2025 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Akari Therapeutics Plc  (NASDAQ: AKTX)


Akari Therapeutics Plc's ROA from the first quarter of 2026 to the first quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Akari Therapeutics Plc's ROA in the first quarter of 2026?
Akari Therapeutics Plc recorded a cumulative net loss of $-28 million during 12 months ending in the first quarter of 2026, resulting in a negative return on assets (ROA) of -58.38%.

However, within the Healthcare sector 632 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Mar 31 2026 quarter, so far to 4061, from total ROA ranking in the fourth quarter of 2025 at 4369.

What is ROA?


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Assets (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter		 (Mar 31 2025)
I. Quarter
Y / Y Total Assets Change -31.5 % 4.59 % 862.25 % 431.54 % 1213.11 %
Y / Y Net Income Change - - - - -
Net Income (TTM) in million -28 -17 -16 -12 -18
Return On Assets (TTM) -58.38 % -33.1 % -30.52 % -29.97 % -59.68 %
AKTX's Total Ranking # 4061 # 4369 # 3808 # 3822 # 4336
Total Assets (TTM) in million 37 54 48 54 54
Seq. Total Assets Change -31.81 % 12.37 % -10.73 % 0.15 % 4.11 %
Seq. Net Income Change - - - - -

AKTX's 5 Years Annual ROA >> Back to AKTX Management Effectiveness >> Compare AKTX ROA to its Competitors


Return On Assets Company Ranking
Within: No.
Industry # 285
Sector # 633
Overall # 4026

Return On Assets Statistics
High Average Low
-31.62 %
-230.17 %
-938.36 %
(Jun 30 2025)   (Jun 30 2024)



  News about Akari Therapeutics Plc Return on Assets ROA

Akari Therapeutics: Navigating Financial Turbulence and Charting New Growth Paths in the Biopharmaceutical Arena,

Akari Therapeutics: A Financial Rebirth Amidst Challenges in the Biopharmaceutical LandscapeOverview of Recent DevelopmentsAkari Therapeutics Plc (Nasdaq: AKTX), a biotechnology company specializing in innovative therapies for cancer treatment, has recently made significant movements in its financial and operational strategy. This is exemplified by the successful pricing of a $7.6 million private placement offering led by existing shareholders, aiming to bolster the company’s cash reserves while focusing on its promising pipeline, including the novel spliceosome inhibitor payload antibody-drug conjugate (ADC) technology. However, the backdrop of these achievements features a cumulative net loss of $26 million in the 12 months ending in Q3 2024, leading to a staggering negative return on assets (ROA) of -696.98%. This troubling statistic places Akari in stark contrast to its peers within the healthcare sector, where 937 other companies boast a higher ROA.Key Financial Metrics- Private Placement Financing: Successful raise of approximately $7.6 million.- Q3 2024 Results: Cumulative net loss of $26 million; ROA of -696.98%.- Market Position: Improved their ROA ranking from 4556 in Q2 2024 to 4397 by Q3 2024.- Regaining Nasdaq Compliance: Achieved compliance with Nasdaq requirements after addressing equity deficiencies.



Financial Statements
Akari Therapeutics Plc's Assets $ 37 million AKTX's Balance sheet
Akari Therapeutics Plc's Income $ -14 million Quarterly AKTX's Income Statement
AKTX's Income by Division See AKTX's Income by Division



Annual Return On Assets (Dec 31 2025)
FY 2025		 (Dec 31 2024)
FY 2024		 (Dec 31 2023)
FY 2023		 (Dec 31 2022)
FY 2022		 (Dec 31 2021)
FY 2021
Y / Y Total Assets Change -0.44 % 460.17 % -71.64 % 154.07 % -17.8 %
Total Assets in million 54 54 10 34 13
Y / Y Net Income Change - - - - -
Net Income in million -17 -20 -13 -13 -17
Annual Return On Assets -32.12 % -36.59 % -132.84 % -38.44 % -130.02 %

AKTX's 5 Years Annual ROA >> Back to AKTX Management Effectiveness >> Compare AKTX ROA to its Competitors



More Return On Assets Ratios
AKTX's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
AKTX's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for AKTX's Competitors
Subscribers only: Roa for Akari Therapeutics Plc's Suppliers
Subscribers only: Return On Assets for AKTX's Customers

You may also want to know
AKTX's Roi AKTX's Inventory Turnover Ratio AKTX's Growth Rates AKTX's Dividend Comparisons
AKTX's Profitability Ratios AKTX's Asset Turnover Ratio AKTX's Dividend Growth
AKTX's Roe AKTX's Valuation Ratios AKTX's Financial Strength Ratios AKTX's Dividend Payout Ratio



Companies with similar Return On Assets at Mar 31 2026, within Healthcare Sector ROA

Date modified: 2026-09-26T07:11:46+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.